The 2019 EULAR/ACR Classification Criteria as Predictor of Organ Damage in Systemic Lupus Erythematosus Patients

Last updated: March 10, 2024
Sponsor: Sohag University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Systemic Lupus Erythematosus

Cutaneous Lupus Erythematosus

Lupus

Treatment

N/A

Clinical Study ID

NCT06313151
Soh-Med-24-02-02MD
  • Ages 16-60
  • All Genders

Study Summary

The goal of this observational study is to investigate if the 2019 EULAR/ACR classification criteria can be used to assess organ damage in patients with systemic lupus erythematosus (SLE) and as predictor for prognosis .

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Patient age is above 16 years old
  2. Patient is classified as SLE patient according to 2019 ACR/EULAR classificationcriteria
  3. patient with disease duration more than 6 month.

Exclusion

Exclusion Criteria:

  1. Patient with drug-induced lupus and those with systemic sclerosis or dermatomyositisoverlap syndromes .
  2. patient with disease duration less than 6 month will be excluded.

Study Design

Total Participants: 200
Study Start date:
March 10, 2024
Estimated Completion Date:
March 15, 2026

Study Description

The study will include 200 systemic lupus patient attending Sohag University Hospital from march 2024 to march 2025 in Rheumatology Department.

The patients included in the study will be classified as SLE patient according to 2019 ACR/EULAR classification criteria.

Inclusion criteria:

  1. Patient age is above 16 years old

  2. Patient is classified as SLE patient according to 2019 ACR/EULAR classification criteria

  3. patient with disease duration more than 6 month.

Exclusion criteria:

  1. Patient with drug-induced lupus and those with systemic sclerosis or dermatomyositis overlap syndromes .

  2. patient with disease duration less than 6 month will be excluded.

Methods:

All patient will be selected randomly and undergo a complete history taking and physical examination, The data will be collected and analyzed as the following:

  1. Demographic data: age, gender,sex.

  2. Clinical data:

    O Age of disease onset ,disease duration, time of disease onset, organs involved , O presence of hypertension, hyperlipidemia, or diabetes, O drugs administration of hydroxychloroquine , azathioprine , cyclophosphamide pulse, cyclosporine, mycophenolate mofetil, prednisolone, and use of pulses of methylprednisolone.

  3. disease activity measured by SLEDAI.

Laboratory results:

routine investigations: white cell count, hemoglobin, platelet,serum creatinine, ALT ,AST and urine analysis.

oAntinuclear antibody (ANA) by immunofluorescence and its pattern oANA profile

  • Complement C3,C4.

  • anticardiolipin antibody (ACA), lupus anticoagulant (LA). O Further investigation will be customized to the patient according to their clinical history and examination like abdominal ultra sound,24 hours urine protein ,glumerular filteration rate ,renal biopsy, x-ray on chest or vertebral colon, CT chest or brain, MRI brain , ECG, echo cardiography.

The organ damage assessment with the SLICC/ACR Damage Index (SDI) contains items that represent permanent, irreversible damage in a lupus patient. Items should be present for at least 6 months with the exception that manifestations such as myocardial infarction and stroke are recorded once they occur. Damage is defined for 12 organ systems: ocular (range 0-2), neuropsychiatric (0-6), renal (0-3), pulmonary (0-5), cardiovascular (0-6), peripheral vascular (0-5), gastrointestinal (0-6), musculoskeletal (0-7), skin (0-3), endocrine (diabetes) (0-1), gonadal (0-1), and malignancies (0-2). Damage over time can only be stable or increase, theoretically to a maximum of 47 points(6).

Connect with a study center

  • Sohag University

    Sohag, 82511
    Egypt

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.